Global healthcare company Novo Nordisk A/S (CPH:NOVOB) announced on Monday that it has reached a settlement with Teva Pharmaceuticals USA Inc (Teva) on the US patent litigation case for Victoza (liraglutide).
As a result of this settlement, Teva is licensed to launch a generic version of Victoza as of 22 December 2023.
Under certain circumstances, Teva could launch a generic version of Victoza earlier, but not before 22 March 2023, unless the Victoza patents are no longer in force or there is another generic version of Victoza® on the market.
In the event that Novo Nordisk is granted six months paediatric extension for Victoza, all these above-mentioned timelines will be extended by six months.
All other terms of the agreement are confidential.
This agreement is subject to review by the US Federal Trade Commission and the US Department of Justice.
CivicaScript to distribute biosimilar for chronic inflammatory conditions
Mallinckrodt and Endo complete merger
Zenara Pharma's Sertraline Hydrochloride Capsules generic receives US FDA approval
EQT agrees to acquire majority stake in Adalvo
Mallinckrodt receives Irish High Court ruling to combine with Endo Inc
Accord Healthcare introduces Dehydrated Alcohol Injection for cardiovascular indications
CivicaScript introduces low-cost multiple sclerosis treatment
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Glenmark Therapeutics launches Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC)
AB Science secures Canadian patent for AB8939, completing global IP coverage for AML treatment
Avera joins Civica to help maintain drug supplies
Apotex launches generic version of Tasigna in US market
CivicaScript launches droxidopa for symptomatic neurogenic orthostatic hypotension
Padagis' Naloxone HCl Nasal Spray 4 mg obtains extended shelf-life of 36 months
ANI Pharmaceuticals announces US launch of Nitazoxanide Tablets